文献速递重症综合管理与镇静镇痛儿科与产科急症

口服利培酮、氟哌啶醇或安慰剂对姑息治疗患者谵妄症状的疗效:一项随机临床试验

Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2017-01-01
一句话结论在姑息治疗患者中,针对谵妄诱因的个体化管理与支持策略比加用利培酮或氟哌啶醇更能降低目标痛苦谵妄症状评分并缩短持续时间。

这项双盲、平行组、剂量滴定随机临床试验在澳大利亚11家住院临终关怀或医院姑息治疗服务机构进行,纳入生命受限疾病、谵妄且谵妄症状评分(护理谵妄筛查量表行为、沟通和知觉条目之和)≥1分的患者。患者每12小时接受年龄调整滴定的口服利培酮、氟哌啶醇或安慰剂溶液,共72小时,同时接受支持治疗、谵妄诱因个体化治疗及按需皮下咪达唑仑。意向性治疗分析共247例,第3天利培酮组谵妄症状评分平均比安慰剂组高0.48单位(95%CI 0.09-0.86,P=0.02),氟哌啶醇组平均高0.24单位(95%CI 0.06-0.42,P=0.009);两活性药组锥体外系反应均多于安慰剂组。作者结论认为,个体化管理谵妄诱因和支持策略比加用利培酮或氟哌啶醇更能降低评分并缩短目标痛苦谵妄症状持续时间。

要点

  • 在姑息治疗谵妄患者中,利培酮组第3天谵妄症状评分平均比安慰剂组高0.48单位(95%CI 0.09-0.86,P=0.02)。
  • 氟哌啶醇组第3天谵妄症状评分平均比安慰剂组高0.24单位(95%CI 0.06-0.42,P=0.009)。
  • 与安慰剂相比,利培酮组锥体外系反应更多(0.73;95%CI 0.09-1.37;P=0.03),氟哌啶醇组也更多(0.79;95%CI 0.17-1.41;P=0.01)。
  • 安慰剂组总生存优于氟哌啶醇组(HR 1.73;95%CI 1.20-2.50;P=0.003),安慰剂 vs 利培酮未达统计学显著(HR 1.29;95%CI 0.91-1.84;P=0.14)。
  • 作者结论:个体化管理谵妄诱因和支持策略比加用利培酮或氟哌啶醇更能降低目标痛苦谵妄症状评分并缩短持续时间。

适用人群与场景

  • 接受姑息治疗的生命受限疾病患者,伴谵妄且谵妄症状评分(护理谵妄筛查量表行为、沟通和知觉条目之和)≥1分。
  • 研究在澳大利亚11家住院临终关怀或医院姑息治疗服务机构进行,时间为2008年8月13日至2014年4月2日。

诊断标准与关键阈值

  • 谵妄症状评分:护理谵妄筛查量表行为、沟通和知觉条目之和,严重程度范围0-6分;纳入标准为评分≥1分。

处置流程与药物剂量

  • 所有患者接受支持治疗、谵妄诱因个体化治疗,以及按需皮下盐酸咪达唑仑用于严重痛苦或安全需要。
  • 口服利培酮、氟哌啶醇或安慰剂溶液采用年龄调整滴定剂量,每12小时给药一次,共72小时,根据谵妄症状调整。

研究设计与关键结果

  • 双盲、平行组、剂量滴定随机临床试验,11家中心,247例纳入意向性治疗分析(利培酮82例、氟哌啶醇81例、安慰剂84例);平均(SD)年龄74.9(9.8)岁,女性85例(34.4%),癌症218例(88.3%)。
  • 主要终点:第3天谵妄症状评分较基线的平均组间差异;利培酮组比安慰剂组平均高0.48单位(95%CI 0.09-0.86;P=0.02),氟哌啶醇组比安慰剂组平均高0.24单位(95%CI 0.06-0.42;P=0.009)。
  • 锥体外系反应:利培酮组比安慰剂组多0.73(95%CI 0.09-1.37;P=0.03),氟哌啶醇组比安慰剂组多0.79(95%CI 0.17-1.41;P=0.01)。
  • 总生存:安慰剂组优于氟哌啶醇组(HR 1.73;95%CI 1.20-2.50;P=0.003);安慰剂 vs 利培酮未达统计学显著(HR 1.29;95%CI 0.91-1.84;P=0.14)。

证据类型、等级与局限

  • 证据类型:双盲、平行组、剂量滴定随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在姑息治疗患者中,个体化管理谵妄诱因和支持策略比加用利培酮或氟哌啶醇更能降低目标痛苦谵妄症状评分并缩短持续时间。
  • 研究显示利培酮和氟哌啶醇组谵妄症状评分均高于安慰剂组,且锥体外系反应更多;氟哌啶醇组总生存劣于安慰剂组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Antipsychotics are widely used for distressing symptoms of delirium, but efficacy has not been established in placebo-controlled trials in palliative care.

OBJECTIVE: To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care.

DESIGN, SETTING, AND PARTICIPANTS: A double-blind, parallel-arm, dose-titrated randomized clinical trial was conducted at 11 Australian inpatient hospice or hospital palliative care services between August 13, 2008, and April 2, 2014, among participants with life-limiting illness, delirium, and a delirium symptoms score (sum of Nursing Delirium Screening Scale behavioral, communication, and perceptual items) of 1 or more.

INTERVENTIONS: Age-adjusted titrated doses of oral risperidone, haloperidol, or placebo solution were administered every 12 hours for 72 hours, based on symptoms of delirium. Patients also received supportive care, individualized treatment of delirium precipitants, and subcutaneous midazolam hydrochloride as required for severe distress or safety.

MAIN OUTCOME AND MEASURES: Improvement in mean group difference of delirium symptom score (severity range, 0-6) between baseline and day 3. Five a priori secondary outcomes: delirium severity, midazolam use, extrapyramidal effects, sedation, and survival.

RESULTS: Two hundred forty-seven participants (mean [SD] age, 74.9 [9.8] years; 85 women [34.4%]; 218 with cancer [88.3%]) were included in intention-to-treat analysis (82 receiving risperidone, 81 receiving haloperidol, and 84 receiving placebo). In the primary intention-to-treat analysis, participants in the risperidone arm had delirium symptom scores that were significantly higher than those among participants in the placebo arm (on average 0.48 Units higher; 95% CI, 0.09-0.86; P = .02) at study end. Similarly, for those in the haloperidol arm, delirium symptom scores were on average 0.24 Units higher (95% CI, 0.06-0.42; P = .009) than in the placebo arm. Compared with placebo, patients in both active arms had more extrapyramidal effects (risperidone, 0.73; 95% CI, 0.09-1.37; P = .03; and haloperidol, 0.79; 95% CI, 0.17-1.41; P = .01). Participants in the placebo group had better overall survival than those receiving haloperidol (hazard ratio, 1.73; 95% CI, 1.20-2.50; P = .003), but this was not significant for placebo vs risperidone (hazard ratio, 1.29; 95% CI, 0.91-1.84; P = .14).

CONCLUSIONS AND RELEVANCE: In patients receiving palliative care, individualized management of delirium precipitants and supportive strategies result in lower scores and shorter duration of target distressing delirium symptoms than when risperidone or haloperidol are added.

TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12607000562471.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Agar MR, Lawlor PG, Quinn S, et al. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. JAMA Intern Med. 2017. PMID: 27918778. doi:10.1001/jamainternmed.2016.7491

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。